Irma Veberic – General Manager, Roche Hungary
Irma Veberic, general manager of Roche Hungary, gives her insights on the key issues being faced by the Hungarian healthcare system and the company’s role as a partner in improving…
Address: Budaörs 2040 Edison u. 1. Hungary,Hungary
Tel: +36-23-446-871
Web: http://www.roche-diagnostics.hu/portal/dia/rolunk
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80’000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management.
Irma Veberic, general manager of Roche Hungary, gives her insights on the key issues being faced by the Hungarian healthcare system and the company’s role as a partner in improving…
Hungary has been recognized as one of the largest pharmaceutical and healthcare markets in Central and Eastern Europe, and can obviously not be ignored by Roche. First of all, can…
Providing universal health coverage to the nation’s roughly 10 million citizens, Hungary’s National Health Insurance Fund (OEP) has one of the most comprehensive and complex structures in Europe. The organization’s…
Chronic underfinancing is a common pitfall for many former socialist states and Hungary is no exception. Total health spending ultimately accounted for 8.0 percent of GDP in Hungary in 2014, which…
Mylan Hungary’s Tamas Uri discusses transitioning into both a branded and generic business dedicated company, Mylan’s expansion in Hungary, and how the pharmaceutical industry can be a key player in improving the…
Hungary’s Minister of Foreign Affairs and Trade Péter Szijjártó highlights the significant role that foreign direct investments have played in developing the country’s healthcare and life science sector, while detailing…
György Bodoky, Head of the Oncology Department at Unified Szent István and Szent László Hospital, shares his insights on the state of oncological care in Hungary, the current effects of…
János Burovincz, Managing Director of Patent, shares his insights on building a company from scratch, the importance of maintaining a diverse portfolio that can quickly adapt to market needs as…
GSK Hungary’s Claire Roger discusses the value of ethical promotion both in improving transparency and benefiting all stakeholders. She further describes the strategic role and economic impact of GSK’s vaccine plant in…
Róbert Ésik, President of the Hungarian Investment Promotion Agency (HIPA), shares his insights into what makes Hungary such an attractive destination for foreign direct investment and ways that the agency…
To effectively reform old habits requires diligence, consistency and, above all, patience. As an introduction for our readers, could you describe the initial objectives that you set for yourself…
Veronika Ferencz, Sales and Marketing Director for Exeltis Hungary, discusses the evolving and expanding footprint of the company in Hungary, the challenges strict regulations on food supplements are causing, as…
The leadership of Meditop discuss their history as the first non-privatized, private Hungarian pharmaceutical company, their ongoing strategies for growth in the country, and their evolving portfolio abroad. They also…
The recently appointed CEO of Servier Hungary, Dr. Jan Frederic Kesselhut highlights his initial perceptions of the Hungarian pharmaceutical market and depicts the significant role that the Servier Research Institute…
See our Cookie Privacy Policy Here